Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Malignancy

NCT04694781 is registered in ClinicalTrials.gov with Lyvgen Biopharma Holdings Limited as lead sponsor.

NCT NCT04694781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04694781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Malignancy
Lead sponsor
Lyvgen Biopharma Holdings Limited
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2021
Completion date
October 31, 2023
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer